Practical aspects of "Heart Protection Studies"


Cite item

Full Text

About the authors

A V Susekov

References

  1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994; 344: 1383-1389.
  2. Shepherd J., Cobbe S. M., Isles C. G. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995; 333: 1301-1307.
  3. Sacks F. N., Pfeffer M. A., Moye L. A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. N. Engl. Med. 1996; 335: 1001-1009.
  4. The Long-term Prevention with Pravastatin in Ischemic Disease (LIP1L) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998; 339: 1349-1357.
  5. Downs J. R., Clearfield M., Weis S. et al. for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. J. A. M. A. 1998; 279: 1615-1622.
  6. Shepherd J., Blauw G. J., Murphy M. B. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360: 1623-1630.
  7. The ALLHAT Officers and Coordinators for. the ALLHAT Collaborative Research Group. Major Outcomes in moderately hypercholesterolemic, hypertensive patients randomized to Pravastatin vs Usual Care. The antihypertensive and lipid-lowering treatment to prevent Heart Attack Trial (ALLHAT LLT). J. A. M. A. 2002; 288(23): 2898-3007.
  8. Collins R. Heart Protection Study-Main results. Late-breaking clinical trials. In: American Heart Association. Scientific sessions 2001, 13 November 2001. Anahaim, California; 2001: 11. USA.
  9. Heart Protection Study Collaborative Group. MRC/BNF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk patients: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
  10. Сусеков А. В., Зубарева М. Ю., Кухарчук В. В. Heart Protection Study - Исследование защиты сердца (по материалам симпозиума). Клин, фармакол. и тер. 2002, 1; 71-74.
  11. Сусеков А. В. Исследование защиты сердца - новые стандарты в лечении атеросклероза. Атмосфера. Кардиология 2002; 2(3): 14-16.
  12. Wood D., Backer G. D., Faergeman О. et al. Prevention of coronary heart disease in clinical practice: Recommendation of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atheroclerosis 1998; 140: 199-270.
  13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. A. M. A. 2001; 295(19): 2486-2497.
  14. Wierzbicki A. S., Reynolds T. M., Gill K. et al. A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease. J. Cardiovasc. Risk 2000; 7: 63-71.
  15. The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am. J. Cardiol. 1997; 79: 756-762.
  16. Gotto A. M., Whitney E., Stein E. et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study. Circulation 2000; 101: 477-484.
  17. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 1992: 33: 1569-1582.
  18. Groot E., Jukema J. W., Bruschke A. V. et al. Effects of lipid-low ering by pravastatin on progression and regression of coronary artery disease in synptomatic men with normal to moderate elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2538-2540.
  19. Herd J. A., Ballantyne C. M., Farmer J. A. et al. Effects of Fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and coronary aterosclerosis study ([LCAS]).
  20. Sacks F. M., Pasternak R. C., Gibson С. М. et al. for the Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentration in normocholesteroleamic patients. Lancet 1994; 334: 1182-1186.
  21. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N. Engl. J. Med. 1997; 336: 153-162.
  22. Thompson G. R. Angiographic trials of lipid-lowering therapy: end of an era? Br. Heart. J. 1995; 74: 343-347.
  23. Thompson G. R., Holyer J., Waters D. D. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr. Opin. Lipidol. 1995; 6: 386-388.
  24. Thompson G. R. What targets should lipid-modulationg therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis 1997; 131: 1-5.
  25. Thompson G. R., Maher V. G. M., Matthews S. et al. Familial Hypercholesterolemia! Regression Study: a randomized trial of low-density lipoprotein apheresis. Lancet 1995; 345: 811-816.
  26. Сусеков А. В. Обоснование увеличения доз статинов в клинической практике. Тер. арх. 2001; 4:76-80.
  27. American Heart Association. 2001 Heart and Stroke statistical update. Available at: http://www.americanheart.org/statistics.
  28. Knopp R. H. Risk factors for coronary artery disease in women. Am. i. Cardiol. 2002; 89(suppl.): 28E-35E.
  29. Crouse J. R., Frohlich J., Ose L. et al. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-l. Am. J. Cardiol. 1999; 83(10): 1476-1477.
  30. Shepherd J., Blauw С. J., Murphy M. B. et al. and al on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360: 1623-1629.
  31. Cheng H., Rogers J. D., Sweany A. E. et al. Infleunce of age gender on the plasma profiles of 3-hydroxy-3-methuIglutaryl coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm. Res. 1992; 9: 1629-1633.
  32. Grundy S. M., Benjamin I. J., Burke G. L. et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from American Heart Association. Circulation 1999; 100: 1134-1146.
  33. Diabetes statistics. National Diabetes Information Clearinghouse. Bethesda, Md: National Institute of Diabetes and Digestive and kidney Diseases; 1999. N1H publication 99-3926.
  34. Pyorala K., Laakso M. et al. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab. Rev. 1987; 3: 463-524.
  35. Goldberg R. В., Mellies M. J., Sacks F. M. et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998; 23: 2513-1529.
  36. Pyorala K., Pedersen T. R., Kjeksus J. et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 199720: 614-620.
  37. Diabetes Atherosclerosis Intervention Study Investigators. Effects of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001; 357: 905-910.
  38. Сусеков А. В., Творогова М. Г., Суркова Е. В. и др. Лескол при лечении гиперлипидемии у пациентов с инсулинонезависмым сахарным диабетом. Кардиология 1998; 3: 33-36.
  39. Proscpective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13000 strokes in 45000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-1653.
  40. Gorelick P. В., Sacco R. L., Smith D. B. et al. Prevention of a first stroke. A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. J. A. M. A. 1999; 281: 1112-1120.
  41. Plehn J. F., Davis B. R., Saks F. M. et al. Reduction of stroke incidence after myocardial infarction with pravastatin. The Cholesterol and Recurrent Events (CARE) Study. Circulation 1999; 99: 216-223.
  42. Hebert P., Gaziano J. M., Chan K. S., Hennekes С. Н. Cholesterol lowering with statin drugs, risk of stroke and total mortality. J. A. M. A. 1997; 278: 313-321.
  43. Crouse J. R., Byington G., Furberg С. D. HMG-Co-A reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trial data. Atheroslerosis 1998; 138: 11-24.
  44. Crouse J. R. Effects of statins on carotid disease and stroke. Cur. Opin. Lipidol. 1999; 10: 535-541.
  45. Steinberg D., Witztum J. L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulasion 2002; 105(17): 2107-2111.
  46. Brown В., Xue-Qiao Z., Chait A. et al. Simvastatin and niacin, antioxidant vitamins or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001; 345: 1583-1592. http://www.bda.uk.com.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies